Clinical Trial Update: Phase I/II Study of Combination of Sorafenib, Vorinostat, and Bortezomib for the Treatment of Acute Myeloid Leukemia With Complex- or Poor-risk (Monosomy 5/7) Cytogenetics or FLT3-ITD Positive Genotype [Phase 1, Phase 2]

View source ↗

Summary

Phase I/II trial evaluating a combination of sorafenib, vorinostat, and bortezomib in adults with acute myeloid leukemia, completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• Bortezomib (bortezomib)
• Sorafenib (Sorafenib)
• Vorinostat (vorinostat)

Snippet

Sponsor: Hamid Sayar | Conditions: Acute Myeloid Leukemia | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2018-08-17